Aquestive Therapeutics Corporate Profile
Aquestive Therapeutics is a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs. The Company has a late-stage proprietary product pipeline focused on the treatment of CNS diseases, as well as orally administered complex molecules that it believes can be alternatives to invasively-administered standard of care therapies. The most advanced product candidates developed to treat varying CNS diseases include Libervant and AQST-117 (Riluzole). SympazanTM (clobazam), oral film for the adjunctive therapy of seizures associated with Lennox-Gastaut syndrome (LGS), received FDA approval. As the leader in developing and delivering drugs via its PharmFilm® technology, the Company also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the Company with its partners has a portfolio of development-stage products and commercialized products, such as Suboxone, the market leader for the treatment of opioid dependence.
Copyright West LLC. Minimum 15 minutes delayed.